Literature DB >> 16793531

Creating more effective antidepressants: clues from the clinic.

Kurt Rasmussen1.   

Abstract

Antidepressant medications have eased the suffering of millions of people. In addition to treating depression, antidepressant drugs also treat several anxiety disorders. Unfortunately, there are problematic limitations with antidepressant agents, including a delayed therapeutic response and insufficient efficacy. Emerging evidence shows that atypical antipsychotic agents can be used as augmentation therapy in patients with poor responses to antidepressants. Future drugs combining key features of antidepressant and atypical antipsychotic agents could offer new promise for patients suffering from obsessive-compulsive disorder, post-traumatic stress disorder, panic disorder, generalized anxiety disorder and depression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16793531     DOI: 10.1016/j.drudis.2006.05.004

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  7 in total

Review 1.  Structure-based systems biology for analyzing off-target binding.

Authors:  Lei Xie; Li Xie; Philip E Bourne
Journal:  Curr Opin Struct Biol       Date:  2011-02-01       Impact factor: 6.809

2.  Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.

Authors:  William V Bobo; Richard C Shelton
Journal:  Neuropsychiatr Dis Treat       Date:  2009-07-02       Impact factor: 2.570

Review 3.  Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Authors:  Yael Chertkow; Orly Weinreb; Moussa B H Youdim; Henry Silver
Journal:  J Neural Transm (Vienna)       Date:  2009-07-04       Impact factor: 3.575

Review 4.  Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Authors:  Mark J Millan
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

5.  Tinnitus: network pathophysiology-network pharmacology.

Authors:  Ana B Elgoyhen; Berthold Langguth; Sven Vanneste; Dirk De Ridder
Journal:  Front Syst Neurosci       Date:  2012-01-25

6.  UPLC-Tandem Mass Spectrometry Method for Simultaneous Determination of Fluoxetine, Risperidone, and Its Active Metabolite 9-Hydroxyrisperidone in Plasma: Application to Pharmacokinetics Study in Rats.

Authors:  Essam Ezzeldin; Nisreen F Abo-Talib; Marwa H Tammam
Journal:  J Anal Methods Chem       Date:  2017-06-01       Impact factor: 2.193

7.  Exploring the utility of RDoC in differentiating effectiveness amongst antidepressants: A systematic review using proposed psychometrics as the unit of analysis for the Negative Valence Systems domain.

Authors:  Andrew Hui
Journal:  PLoS One       Date:  2020-12-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.